Exogenous Glucagon-like Peptide 2 Counteracts Exogenous Cholecystokinin-induced Gallbladder Contraction in Healthy Men

What Was Tested

Researchers studied Cholecystokinin (CCK) in this randomized controlled trial publication.

Here, the researchers assessed the effect of exogenous GLP-2 on gallbladder motility in the fasted state of healthy men with and without infusion of the potent gallbladder-contracting hormone cholecystokinin (CCK).

Who Took Part

The abstract describes 15 participants taking part.

The age groups tagged for this paper are young adults and adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Cholecystokinin (CCK) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Cholecystokinin (CCK).

A placebo (an inactive look-alike) gave the Cholecystokinin (CCK) group a baseline to be compared against.

Each person switched between Cholecystokinin (CCK) and the comparison at some point, usually with a gap in between.

Gallbladder volume was measured at baseline and throughout the 4-hour study day using ultrasonography.

What Was Measured

Topics PubMed links to this paper include Gallbladder, Glucagon-Like Peptide 2, Cholecystokinin, Gallbladder Emptying, Muscle Contraction and Healthy Volunteers.

The authors tagged it with the keywords CCK, GLP-1 and GLP-2.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cholecystokinin (CCK) in 15 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Cholecystokinin (CCK) compound page, all human trials.